Feline Hypertrophic Cardiomyopathy (HCM) is the most common heart disease in domestic cats, affecting approximately 14.7% (nearly 1 in 7) of apparently healthy, subclinical cats. It is characterized by concentric hypertrophy of the left ventricle without an obvious systemic or metabolic cause (such as systemic hypertension or hyperthyroidism).

For pet owners and general veterinary practitioners, HCM presents a classic clinical dilemma: a healthy, active cat comes in for a routine annual exam, and the veterinarian detects a heart murmur or gallop rhythm. Does this asymptomatic cat need an expensive echocardiogram right away? If HCM is confirmed, what is the cat's actual life expectancy, and does starting medication early change the outcome?

This guide provides a definitive overview of feline HCM. It evaluates the asymptomatic murmur diagnostic pathway, translates the ACVIM 2020 Consensus Guidelines staging framework, analyzes major arterial thromboembolism (ATE) prevention trials (FATCAT and SUPER-CAT), details breed-specific genetics (Maine Coon, Ragdoll, Sphynx), outlines acute emergency resuscitation protocols and home resting respiratory rate monitoring, and presents stage-stratified survival evidence.

---

Direct Answer: Quick Clinical Decision Framework

For clinicians and pet owners managing an asymptomatic cat with a heart murmur or confirmed HCM:

• The Asymptomatic Murmur Decision: Recommend an echocardiogram. An echocardiogram is the only diagnostic tool that can confirm HCM, measure left ventricular wall thickness, evaluate left atrial size, and rule out innocent murmurs or dynamic right ventricular outflow tract obstruction (DRVOTO). Approximately 50% of heart murmurs in cats are innocent or non-cardiac, but an echo is essential to identify the subclinical cats at risk of sudden cardiac death or clot formation.
• ACVIM 2020 Staging Thresholds:
  • Stage A: Predisposed breeds (Maine Coon, Ragdoll) with normal echocardiograms. No treatment.
  • Stage B1 (Low Risk): Mild-to-moderate wall hypertrophy (≥ 6.0 mm) with a normal left atrium (LA:Ao < 1.6). Do NOT start medications (beta-blockers like atenolol have NOT been shown to prolong survival in subclinical HCM).
  • Stage B2 (High Risk): Moderate-to-severe hypertrophy WITH left atrial enlargement (LA:Ao ≥ 1.6 or left atrial diameter > 16 mm). Initiate antithrombotic therapy immediately (Clopidogrel 18.75 mg q24h) to prevent fatal saddle thrombus formation.
  • Stage C (Active or Past CHF / ATE): Congestive heart failure (pulmonary edema, pleural effusion) or Arterial Thromboembolism. Treat with furosemide, clopidogrel, oxygen, and pimobendan/ACE-inhibitors as indicated.
  • Stage D (Refractory CHF): Advanced heart failure non-responsive to standard therapy.
• ATE Prevention Gold Standard: Clopidogrel (Plavix, 18.75 mg q24h) is the proven antithrombotic drug of choice. The landmark FATCAT trial showed clopidogrel more than doubled the median time to a recurrent ATE versus aspirin (442 vs 192 days) and lowered the recurrence rate from about 75% to about 49%. The 2025 SUPER-CAT trial found rivaroxaban (2.5 mg q24h) produced recurrence and survival outcomes comparable to clopidogrel, making it a reasonable alternative.

ACVIM 2020 staging at a glance:

Stage	Finding	Action
A	Predisposed breed (Maine Coon, Ragdoll), normal echo	No treatment; screen periodically
B1	HCM present (LV wall ≥ 6 mm), normal left atrium (LA:Ao < 1.6)	No medication; recheck echo in 6–12 months
B2	HCM with left atrial enlargement (LA:Ao ≥ 1.6)	Start clopidogrel 18.75 mg q24h to prevent ATE
C	Current or past CHF (pulmonary edema/effusion) or saddle thrombus	Furosemide + clopidogrel + oxygen ± pimobendan/ACE inhibitor
D	Refractory CHF	Escalate diuresis (torsemide, spironolactone)

---

The Asymptomatic Murmur Decision: Do We Need an Echo?

Finding a systolic heart murmur during a routine physical exam is the single most common presentation of subclinical HCM. However, the presence or absence of a murmur correlates poorly with disease severity:

• Murmurs do not equal severe disease: Up to 50% of cats with confirmed HCM have no detectable heart murmur.
• Murmurs can be innocent: Approximately half of cats evaluated for an asymptomatic murmur have normal echocardiograms or benign dynamic outflow tract narrowing without structural heart disease.
• Gallop Rhythms are High Risk: Unlike a murmur, a gallop sound (S₃ or S₄) or persistent arrhythmia in a cat is strongly associated with moderate-to-severe HCM and increased risk of sudden death.

Diagnostic Workup Pathway

When an asymptomatic murmur is detected, the workup runs on two tracks at once: ruling out secondary causes of wall thickening, and confirming and staging HCM on echocardiography.

Track	Steps
Rule out secondary causes (HCM phenocopies)	Total T4 (rule out hyperthyroidism); systolic blood pressure (rule out systemic hypertension); plasma NT-proBNP if echocardiography is not available
Echocardiogram (gold standard)	Measure LV wall thickness; evaluate LA:Ao ratio and left atrial size; check for spontaneous echocardiographic contrast or a left atrial appendage thrombus; then stage per ACVIM 2020

If the secondary-cause workup is normal, proceed to echocardiography to stage the patient.

1. Rule Out Secondary Wall Thickening (HCM Phenocopies): Before diagnosing primary HCM, evaluate thyroid status (Total T4) to rule out hyperthyroidism in cats and measure Systolic Blood Pressure to rule out systemic hypertension using an accurate unit per our blood pressure screening in cats guide. Both conditions cause secondary left ventricular concentric hypertrophy.
2. Echocardiogram (Gold Standard): Echocardiography by a trained sonographer or veterinary cardiologist is the definitive diagnostic modality. A diastolic left ventricular wall thickness (interventricular septum or LV free wall) ≥ 6.0 mm confirms HCM (normal wall thickness is < 5.0 mm; 5.0 - 5.9 mm is equivocal/grey zone).
3. NT-proBNP Biomarker Testing: If an echocardiogram is financially inaccessible or unavailable locally, a quantitative plasma NT-proBNP test provides risk stratification. A value > 100 pmol/L indicates significant myocardial stretch and warrants diagnostic imaging; values > 270 pmol/L strongly correlate with left atrial enlargement and high risk of heart failure.

---

Complete Differential Diagnosis Matrix for Feline Systolic Murmurs

When auscultating a systolic heart murmur in a feline patient, clinicians must systematic differentiate structural cardiac disease from innocent or dynamic flow murmurs:

Murmur Cause / Etiology	Murmur Location & Quality	Echocardiographic Features	Clinical Management Action
Primary HCM (SAM Positive)	Grade II–IV/VI systolic murmur at left sternal border.	Concentric LV hypertrophy (≥ 6.0 mm); Systolic Anterior Motion of mitral valve.	ACVIM Staging; initiate Clopidogrel at Stage B2.
Primary HCM (SAM Negative)	Often no murmur or soft Grade I–II/VI murmur.	Concentric LV hypertrophy (≥ 6.0 mm); no LVOTO.	ACVIM Staging; regular echocardiographic follow-up.
DRVOTO (Dynamic RV Outflow)	Grade II–III/VI mid-systolic crescendo-decrescendo murmur.	Dynamic narrowing of right ventricular outflow tract; normal LV walls.	Innocent / Benign. No treatment required. Reassure owner.
Systemic Hypertension	Grade II–III/VI systolic murmur; often variable.	LV wall thickening secondary to pressure overload; SBP ≥ 160 mmHg.	Antihypertensive therapy (Amlodipine / Telmisartan).
Hyperthyroidism	Grade II–IV/VI systolic murmur + tachycardia (> 220 bpm).	High-output cardiac state; LV wall thickening; elevated serum T4.	Anti-thyroid therapy (Methimazole / I-131).
Severe Anemia / Hemodilution	Grade I–III/VI soft physiological flow murmur.	Normal cardiac anatomy; decreased blood viscosity; low Hct (< 20%).	Investigate and treat underlying cause of anemia.
Congenital Heart Disease (VSD / SAS)	Grade III–VI harsh systolic murmur; variable location.	Ventricular septal defect jet or subaortic stenosis ridge on Color Doppler.	Cardiology referral for specialized defect management.

---

Differential Diagnosis & Cardiomyopathy Phenocopies

Not all thick left ventricular walls stem from primary genetic HCM. Clinicians must differentiate HCM from other feline cardiomyopathies and secondary phenocopies:

Disease / Phenocopy	Primary Pathophysiology	Key Diagnostic Features	Primary Management Difference
Primary HCM	Genetic sarcomeric protein defect; concentric LV hypertrophy.	Diastolic LV wall ≥ 6.0 mm; normal T4 & BP.	ACVIM Staging; Clopidogrel at Stage B2.
Systemic Hypertension	Vascular pressure overload driving compensatory LV hypertrophy.	SBP ≥ 160 mmHg; fundic tortuosity / hemorrhage.	Antihypertensive therapy (Amlodipine / Telmisartan); wall thickening may reverse.
Hyperthyroidism	Excessive T3/T4 driving hyperdynamic state & LV hypertrophy.	Total T4 > 4.0 ug/dL; tachycardia, weight loss.	Methimazole / I-131; cardiac changes frequently regress after euthyroid state restored.
Transient Myocardial Thickening (TMT)	Acute reversible LV hypertrophy (often post-stress or myocarditis).	Younger cats; acute CHF that completely resolves over 3–6 months.	Supportive CHF care; medications can often be discontinued once wall thins.
Restrictive Cardiomyopathy (RCM)	Severe endomyocardial fibrosis; normal wall thickness but massive LA/RA enlargement.	LA/RA enlargement without LV hypertrophy; severe diastolic dysfunction.	High risk of ATE and CHF; managed similarly to Stage C HCM.
Dilated Cardiomyopathy (DCM)	Systolic failure; thin LV walls with dilated LV lumen (Taurine deficiency or genetic).	Fractional shortening < 20%; thin walls, large chamber.	Taurine supplementation (500 mg q12h) + Pimobendan.

---

Advanced Echocardiographic Indicators of Clot Risk

While left ventricular wall thickness defines the diagnosis of HCM, left atrial mechanics predict mortality and thrombosis. Three echocardiographic findings mark a cat as high-risk for clot formation (Stage B2 and C): an enlarged left atrium (LA:Ao ≥ 1.6 or LA diameter > 16 mm), spontaneous echocardiographic contrast ("smoke") in the left atrium, and slow left atrial appendage flow velocity (< 0.20 m/s).

• LA:Ao Ratio (≥ 1.6): Measured in the parasternal short-axis view at the heart base. An LA:Ao ≥ 1.6 indicates moderate enlargement; LA:Ao ≥ 2.0 indicates severe enlargement.
• Spontaneous Echocardiographic Contrast (SEC / "Smoke"): Micro-aggregates of red blood cells moving slowly in the left atrium, appearing as swirling grey smoke on 2D imaging. SEC is an immediate precursor to thrombus formation.
• Left Atrial Appendage Flow Velocity (< 0.20 m/s): Pulsed-wave Doppler placed inside the left atrial appendage measures peak ejection velocity. Normal velocity is > 0.40 m/s. A velocity < 0.20 m/s indicates severe stasis and high risk of immediate thromboembolism.
• Systolic Anterior Motion (SAM) of the Mitral Valve: Dynamic motion where the anterior mitral valve leaflet is pulled toward the interventricular septum during systole, creating dynamic left ventricular outflow tract obstruction (LVOTO) and mitral regurgitation.

---

ACVIM 2020 Staging & Treatment Protocol

The 2020 ACVIM Consensus Guidelines reorganized feline cardiomyopathy into four functional stages to guide therapy and prognosis:

ACVIM Stage	Clinical Definition	Echocardiographic Criteria	Pharmacologic Management SOP
Stage A	At-risk / Predisposed	Normal heart structure; known genetic mutation or high-risk breed.	No treatment. Annual clinical screening.
Stage B1	Low-risk Subclinical HCM	LV Wall ≥ 6.0 mm; Left Atrium normal (LA:Ao < 1.6, LA max diameter < 16 mm).	No treatment. Atenolol is NOT recommended. Recheck echo in 6–12 months.
Stage B2	High-risk Subclinical HCM	LV Wall ≥ 6.0 mm; Left Atrium enlarged (LA:Ao ≥ 1.6, LA max diameter ≥ 16 mm).	Start Clopidogrel (18.75 mg PO q24h). Consider atenolol only if severe DRVOTO is present.
Stage C	Active or Past CHF / ATE	Left atrial enlargement + Pulmonary Edema, Pleural Effusion, or ATE episode.	Acute: Oxygen, Furosemide (1–2 mg/kg IV/IM), Clopidogrel. Chronic: Furosemide, Clopidogrel, Pimobendan, ACE inhibitor.
Stage D	Refractory CHF	Heart failure signs recurring despite high-dose furosemide and standard Stage C therapy.	Torsemide (replace furosemide), spironolactone, add secondary vasodilators/diuretics.

The Beta-Blocker Myth in Subclinical HCM

Historically, clinicians frequently prescribed the beta-blocker atenolol to cats with asymptomatic HCM to reduce heart rate and dynamic outflow obstruction. However, the ACVIM 2020 consensus explicitly states that atenolol has NOT been shown to prolong survival or delay the onset of CHF in Stage B1 or B2 cats. Beta-blockers are reserved primarily for cats with severe dynamic right/left ventricular outflow tract obstruction (DRVOTO) causing clinical presyncope or severe tachyarrhythmias.

---

Emergency Resuscitation SOP for Acute CHF & Saddle Thrombus (ATE)

When a cat with HCM presents in acute respiratory distress (Stage C CHF) or sudden hindlimb paralysis (acute ATE), rapid stabilization without stress is vital:

Acute Congestive Heart Failure (CHF) Triage SOP

1. Flow-By Oxygen & Oxygen Cage: Immediately place the cat in an oxygen cage (40-50% FiO₂). Do NOT attempt thoracic radiographs or invasive blood draws on a dyspneic cat — stress can precipitate fatal cardiac arrest.
2. Low-Stress Sedation: Administer Butorphanol (0.2 - 0.3 mg/kg IM or SC). Butorphanol reduces anxiety and respiratory drive without significant cardiovascular depression.
3. Acute Diuresis: Administer Furosemide (1.0 - 2.0 mg/kg IV or IM). Repeat every 1 to 2 hours until respiratory rate decreases below 40 breaths/min. Alternatively, initiate a Furosemide Constant Rate Infusion (CRI) at 0.5 - 1.0 mg/kg/hr.
4. Therapeutic Thoracocentesis: If point-of-care ultrasound (POCUS) reveals significant pleural effusion, perform ultrasound-guided thoracocentesis (7th–8th intercostal space) using a 21-gauge butterfly needle and 3-way stopcock. Removing pleural fluid provides immediate respiratory relief.

Acute Arterial Thromboembolism (ATE) Triage SOP

Acute ATE classically presents as the "5 Ps" in a hind limb: Pain (severe vocalization), Paresis or paralysis, Pulselessness of the femoral artery, Pallor or cyanosis of the paw pads, and Poikilothermia (cold limbs).

ATE prevention evidence to start in Stage B2:

Trial	Drug	Result
FATCAT (Hogan 2015)	Clopidogrel 18.75 mg q24h	More than doubled median time to recurrent ATE vs aspirin (442 vs 192 days); recurrence ~49% vs ~75%
SUPER-CAT (Brainard 2025)	Rivaroxaban 2.5 mg q24h	Recurrence and survival comparable to clopidogrel — a reasonable alternative

1. Analgesia (Immediate Priority): Saddle thrombus causes excruciating ischemic muscle pain. Administer pure mu-opioids immediately (Methadone 0.2 - 0.3 mg/kg IV/IM or Buprenorphine 0.02 - 0.03 mg/kg IV/IM).
2. Anticoagulation: Initiate Low Molecular Weight Heparin (Dalteparin 100 IU/kg SC q9h or Enoxaparin 1.0 mg/kg SC q6h) alongside oral Clopidogrel (18.75 mg loading dose) to prevent further clot expansion.
3. Monitor Reperfusion Hyperkalemia: As ischemic limb tissues regain microvascular perfusion, potassium and toxic metabolites flush back into systemic circulation. Monitor ECG continuously for hyperkalemic tented T-waves and loss of P-waves; treat severe hyperkalemia with calcium gluconate and regular insulin/dextrose.

---

Clinical Evidence Base for ATE Prevention

1. The FATCAT Trial (Hogan et al., 2015)

The landmark FATCAT (Feline Arterial Thromboembolism Clopidogrel vs. Aspirin Trial) evaluated secondary ATE prevention in cats with cardiomyopathy:

• Study Design: Prospective, randomized clinical trial comparing clopidogrel (18.75 mg q24h) versus aspirin (81 mg every 72 hours) in cats following a first episode of ATE.
• Key Results: Clopidogrel significantly prolonged the median time to a recurrent cardiogenic ATE (the primary endpoint) to 442 days, compared with only 192 days for aspirin.
• Recurrence Rates: Overall ATE recurrence was about 49% in the clopidogrel group versus 75% in the aspirin group (19 of 39 cats versus 27 of 36 cats).
• Clinical Conclusion: Clopidogrel is superior to aspirin and represents the gold-standard antithrombotic therapy for cats in Stage B2, C, and D HCM.

2. The SUPER-CAT Trial (Brainard et al., 2025)

The SUPER-CAT Trial published in JAVMA (2025) evaluated the direct factor Xa inhibitor rivaroxaban (2.5 mg q24h) versus clopidogrel:

• Key Finding: Rivaroxaban produced recurrence and survival outcomes comparable to clopidogrel (ATE recurrence 10 of 26 cats / 39% on rivaroxaban versus 7 of 19 / 37% on clopidogrel; median time to recurrence 513 vs 663 days), making it a reasonable alternative for cats that cannot tolerate clopidogrel (such as severe bitter-taste aversion or salivation).

---

Home Monitoring: Resting Respiratory Rate (RRR) Target

For pet owners managing a cat in Stage B2 or Stage C HCM, tracking the Resting Respiratory Rate (RRR) at home is the most sensitive early warning system for impending congestive heart failure (pulmonary edema).

Home RRR SOP for Pet Owners

1. Timing: Count the cat's chest rises for 60 seconds while the cat is sleeping soundly or deeply resting (not purring, playing, or eating).
2. Normal Target: Normal sleeping respiratory rate in cats is < 30 breaths per minute (typically 15 to 25 breaths/min).
3. Action Threshold:
   • RRR < 30 bpm: Stable. Continue current medication schedule.
   • RRR 30 - 40 bpm: Caution. Re-count in 12 hours.
   • RRR > 40 bpm (or persistent elevation over baseline): Contact clinic immediately. Indicates early pulmonary edema; dosage adjustment of furosemide is required before open-mouth breathing develops.

---

Breed Genetics & Testing Standards

HCM has a documented hereditary basis in several purebred cat lines, but genetic testing rules vary significantly by breed:

Breed	Genetic Mutation Identified	Inheritance Pattern	Validated Commercial Test	Clinical Guidance
Maine Coon	MYBPC3-A31P (Myosin-binding protein C3)	Autosomal Dominant (Incomplete Penetrance)	Yes (UC Davis VGL / NC State)	Heterozygotes have moderate risk; Homozygotes have high risk of severe early HCM. Negative test does NOT rule out non-A31P HCM.
Ragdoll	MYBPC3-R820W	Autosomal Dominant (Incomplete Penetrance)	Yes (UC Davis VGL / NC State)	Homozygotes frequently develop severe HCM and CHF before 2 years of age.
Sphynx	Polygenic / Unidentified	Unknown	NO (No validated single-gene test)	Beware false claims. Sphynx cats require annual screening echocardiograms by a cardiologist; DNA tests marketed for Sphynx HCM are unvalidated.
British Shorthair	Polygenic / Unidentified	Unknown	NO (No validated single-gene test)	Annual screening echocardiography remains the only valid screening tool for breeding stock.

Critical Genetic Caveat: A positive MYBPC3 DNA test in a Maine Coon or Ragdoll confirms genetic predisposition, but because of incomplete penetrance, not all positive cats develop clinical heart failure. Conversely, a negative genetic test only rules out that specific mutation; it does not guarantee the cat will never develop HCM from other familial gene variants.

---

Prognosis & Stage-Stratified Survival Data

Prognosis in feline HCM varies dramatically depending on the disease stage at initial diagnosis:

Clinical stage	Median survival	Source
Subclinical HCM (Stage B)	~1,129 days (~3 years); many cats far longer	Rush 2002 (260 cats)
CHF (Stage C)	Older reports ~3 months; ~563 days (~18 months) in the Rush 2002 cohort; 12+ months with modern therapy	Rush 2002; modern case series
ATE / saddle thrombus (Stage C)	~184 days (~6 months) for cats that survive the acute episode	Rush 2002

Stage-Stratified Survival Metrics

1. Subclinical HCM (Stage B1 & B2): Asymptomatic cats diagnosed early have a favorable long-term prognosis. In the Rush 2002 cohort (260 cats), the subclinical group had a median survival of about 1,129 days (~3 years), with a wide range (some cats lived roughly 10 years) and many never progressing to heart failure. Stage B1 cats carry the lowest risk; risk rises once the left atrium enlarges (Stage B2).
2. Congestive Heart Failure (Stage C - CHF): Once a cat develops left-sided heart failure (pulmonary edema or pleural effusion), prognosis shortens. Older reports described CHF median survival as short as about 3 months (92 days); by the Rush 2002 cohort the CHF median had already lengthened to about 563 days (~18 months), and modern management with furosemide, clopidogrel, pimobendan, and ACE inhibitors sustains roughly 12 to 18 months, with some cats surviving over 3 years. For background on heart failure protocols, see our congestive heart failure workup and drug guides for furosemide for dogs and cats and pimobendan in heart failure.
3. Arterial Thromboembolism (Stage C - ATE): An acute saddle thrombus carries a guarded-to-poor initial prognosis. Approximately 35% to 50% of cats succumb to or are euthanized during the acute episode due to severe pain or hyperkalemic reperfusion injury. For cats that survive the acute 48-hour hospital phase, median survival with clopidogrel therapy is approximately 6 to 12 months.

---

Frequently Asked Questions

How long can a cat live with hypertrophic cardiomyopathy?

Asymptomatic (Stage B) cats often live for 3 to 5+ years after diagnosis, and some never progress to heart failure. If HCM progresses to congestive heart failure, median survival with daily medication is typically 12 to 18 months. If a cat survives an acute saddle thrombus, median survival is roughly 6 to 12 months.

Can a heart murmur in a cat be completely harmless?

Yes. Roughly 50% of asymptomatic heart murmurs in cats are innocent or non-pathologic (such as dynamic right ventricular outflow tract obstruction or anemia-related flow murmurs). An echocardiogram is the only way to differentiate a harmless murmur from early HCM.

Does clopidogrel (Plavix) prevent blood clots in cats with HCM?

Yes. The FATCAT clinical trial showed clopidogrel (18.75 mg once daily) more than doubled the median time to a recurrent clot versus aspirin (442 vs 192 days) and lowered the recurrence rate from about 75% to about 49%. Per ACVIM 2020 guidelines, clopidogrel should be started as soon as left atrial enlargement (LA:Ao ≥ 1.6) is detected on an echocardiogram (Stage B2).

Can HCM cause sudden death in a cat that seemed healthy?

Yes. HCM is the leading cause of sudden, unexpected death in young to middle-aged indoor cats. Sudden death usually results from acute ventricular arrhythmias or acute unobserved saddle thrombus formation. Syncope (fainting episodes) and gallop heart rhythms are major clinical warning signs of electrical instability.

Why is resting respiratory rate monitoring so important at home?

Counting your cat's breathing rate while sleeping is the earliest way to detect fluid accumulating in the lungs (pulmonary edema). If sleeping respiratory rate rises above 30 breaths per minute, contacting your veterinarian allows for an early adjustment of furosemide before the cat experiences severe respiratory distress.

---

Sources

• ACVIM 2020 Consensus Guidelines: Fuentes VL, Abbott J, Chetboul V, et al. ACVIM consensus guidelines for the classification, diagnosis, and management of cardiomyopathies in cats. Journal of Veterinary Internal Medicine. 2020;34(3):1062-1077. PMID 32243654
• FATCAT Trial (Clopidogrel vs. Aspirin): Hogan DF, Fox PR, Jacob KA, et al. Secondary prevention of cardiogenic arterial thromboembolism in the cat: The Critical Care Clopidogrel Versus Aspirin Trial (FATCAT). Journal of Veterinary Cardiology. 2015;17(S1):S306-S317. PMID 26776588
• SUPER-CAT Trial (Rivaroxaban vs. Clopidogrel): Brainard BM, et al. Rivaroxaban versus clopidogrel for secondary prevention of cardiogenic arterial thromboembolism in cats: The SUPER-CAT trial. Journal of the American Veterinary Medical Association. 2025;263(4). PMID 39693732
• Payne et al. 2015 Feline Cardiomyopathy Prevalence: Payne JR, Brodbelt DC, Luis Fuentes V. Cardiomyopathy prevalence in 780 apparently healthy cats in primary care practice. Journal of Feline Medicine and Surgery. 2015;17(12):1048-1057. PMID 26776583
• Rush et al. 2002 HCM Prognosis: Rush JE, Freeman LM, Fenollosa NK, Brown DJ. Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990-1999). Journal of the American Veterinary Medical Association. 2002;220(2):202-207.
• Cornell Feline Health Center HCM Resource: Cornell University College of Veterinary Medicine. Feline Hypertrophic Cardiomyopathy Educational Guide. Cornell Feline Health